Recursion Pharmaceuticals, Inc.
RXRX
$3.39
-$0.03-0.88%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 586.72% | -73.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 586.72% | -73.08% | |||
| Cost of Revenue | -18.81% | -8.77% | |||
| Gross Profit | 42.81% | -0.77% | |||
| SG&A Expenses | 1.31% | -10.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.09% | -9.25% | |||
| Operating Income | 32.14% | 2.28% | |||
| Income Before Tax | 33.37% | 5.61% | |||
| Income Tax Expenses | 566.67% | -- | |||
| Earnings from Continuing Operations | 33.36% | 5.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.36% | 5.61% | |||
| EBIT | 32.14% | 2.28% | |||
| EBITDA | 35.58% | 0.80% | |||
| EPS Basic | 43.44% | 11.87% | |||
| Normalized Basic EPS | 39.00% | 11.85% | |||
| EPS Diluted | 43.44% | 11.87% | |||
| Normalized Diluted EPS | 39.00% | 11.85% | |||
| Average Basic Shares Outstanding | 17.84% | 7.10% | |||
| Average Diluted Shares Outstanding | 17.84% | 7.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||